New York ? Congressional investigators asked for additional records from Martha Stewart on Tuesday as they widened the probe into her sale of ImClone shares a day before they plummeted.

The House Energy and Commerce Committee requested some of Stewart’s e-mails, records from her business manager and additional information on her phone numbers.

Martha Stewart, chairwoman and CEO of Martha Stewart Omnimedia Inc., remains in the hot seat as congressional investigators on Wednesday requested some of her e-mails, business records and phone information in connection with her sale of shares of ImClone stock.

In a letter to Stewart’s lawyer Tuesday, committee chairman Rep. Billy Tauzin, R-La., and Rep. James D. Greenwood, R-Pa., chairman of the subcommittee on oversight and investigations, again requested an interview with Stewart to clear up discrepancies between her account of the sale and that of her broker and his assistant.

Stewart, chief executive of Martha Stewart Living Omnimedia Inc., has declined to meet with investigators, saying it’s premature. However, her lawyer said they would do everything they could to comply with the committee’s request for additional documents.

Stewart maintains she had an order to sell her stock when it went below $60 and disposed of nearly 4,000 shares on Dec. 27, a day before ImClone stock tanked on the news that the Food and Drug Administration refused to accept the biotech company’s application to review its highly touted cancer drug.

Doubt has been cast on that assertion because she and her Merrill Lynch broker, Peter Bacanovic, differ on when the order was placed. Moreover, Bacanovic’s assistant, Douglas Faneuil, originally said there was such an order but has since changed his story.

Tuesday’s New York Times and Wall Street Journal reported that Faneuil told investigators that Bacanovic ordered him to call Stewart to advise her to sell her shares because ImClone’s founder and members of his family were dumping their shares. Phone records obtained by the committee show no record of such a call, said Ken Johnson, a spokesman for the House committee.

They do have a record of Bacanovic calling Stewart that afternoon, shortly after which she sold her shares.

Furthermore, a statement given under oath by Stewart’s assistant Ann Armstrong said that Bacanovic called Stewart between 10 a.m. and 11 a.m. on Dec. 27. There is no record of that call.

“Clearly someone is lying to us, and we want to find out who it is,” said Johnson. “If Ms. Stewart has been truthful as her lawyers have said, why shouldn’t she tell her story to us under oath?”

Johnson also noted a June 12 letter from Stewart’s lawyer to the committee said she had no inside knowledge about any actions the FDA was taking about ImClone. But it doesn’t address whether she knew that her friend, former ImClone CEO Samuel Waksal, was trying to sell shares and that his daughter had dumped a large block of stock.

Waksal was arrested in June on insider trading charges for allegedly tipping off members of his family to sell ImClone shares. He was indicted Wednesday.